NEJM â Collection Updates for Multiple Sclerosis

EDITORIAL: Oral Therapy for Multiple Sclerosis â Sea Change or Incremental Step?

William M. Carroll, M.B., B.S., M.D., F.R.A.C.P. — Thu, 04Â FebÂ 2010 00:00:00 -05:00

The long-awaited arrival of oral formulations for the treatment of relapsingâremitting multiple sclerosis is welcome news for the estimated 2.5 million people worldwide who have this chronic, disabling disease. Since...

ORIGINAL ARTICLE: A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

Thu, 04Â FebÂ 2010 00:00:00 -05:00

Background: Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsingâremitting...

ORIGINAL ARTICLE: Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

Thu, 04Â FebÂ 2010 00:00:00 -05:00

Background: Fingolimod (FTY720), a sphingosine-1-phosphateâreceptor modulator that prevents lymphocyte egress from lymph nodes, showed clinical efficacy and improvement on imaging in a phase 2 study involving patients with multiple sclerosis.

Methods:...

ORIGINAL ARTICLE: A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

Thu, 04Â FebÂ 2010 00:00:00 -05:00

Background: Oral fingolimod, a sphingosine-1-phosphateâreceptor modulator that prevents the egress of lymphocytes from lymph nodes, significantly improved relapse rates and end points measured on magnetic resonance imaging (MRI), as compared...

CLINICAL IMPLICATIONS OF BASIC RESEARCH: Gray-Matter Injury in Multiple Sclerosis

Richard A. Rudick, M.D., and Bruce D. Trapp, Ph.D. — Thu, 08Â OctÂ 2009 00:00:00 -05:00

Multiple sclerosis has been classified as a disorder affecting the white matter of the central nervous system. Foci of demyelination, scattered throughout the white matter, are conspicuous on gross postmortem...

ORIGINAL ARTICLE: Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy

Thu, 10Â SepÂ 2009 00:00:00 -05:00

We describe progressive multifocal leukoencephalopathy (PML) caused by infection with human polyomavirus JC virus in a patient with multiple sclerosis who was treated with natalizumab. The first PML symptoms appeared...

ORIGINAL ARTICLE: Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab

Thu, 10Â SepÂ 2009 00:00:00 -05:00

We describe the clinical and therapeutic course of a 52-year-old patient with multiple sclerosis in whom progressive multifocal leukoencephalopathy (PML) developed after 12 months of therapy with natalizumab. The patient...

ORIGINAL ARTICLE: Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab

Thu, 10Â SepÂ 2009 00:00:00 -05:00

Background: Progressive multifocal leukoencephalopathy (PML) occurs in a fraction of patients with multiple sclerosis who were treated with natalizumab. Most adults who are infected with the JC virus, the etiologic...

PERSPECTIVE: Reemergence of PML in Natalizumab-Treated Patients â New Cases, Same Concerns

Thu, 10Â SepÂ 2009 00:00:00 -05:00

When progressive multifocal leukoencephalopathy (PML), a rare demyelinating disease induced by JC virus, appeared in 2004 as a complication of natalizumab treatment for multiple sclerosis, a more common demyelinating disease,...

BOOK REVIEW:

Thu, 11Â DecÂ 2008 00:00:00 -05:00

This slim book contains 134 pages of text and 57 pages of notes and bibliographic references. Many of the references will not be readily available to most readers. The work...

EDITORIAL: Multiple Lessons for Multiple Sclerosis

Stephen L. Hauser, M.D. — Thu, 23Â OctÂ 2008 00:00:00 -05:00

Multiple sclerosis is a cruel disease. It strikes young adults, runs a chronic, unpredictable course, and is eventually disabling for many patients.1 Both inherited and environmental factors influence the risk...

ORIGINAL ARTICLE: Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

The CAMMS223 Trial Investigators — Thu, 23Â OctÂ 2008 00:00:00 -05:00

Background: Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis.

Methods: In this phase 2, randomized, blinded trial involving...

ORIGINAL ARTICLE: B-Cell Depletion with Rituximab in RelapsingâRemitting Multiple Sclerosis

Thu, 14Â FebÂ 2008 00:00:00 -05:00

Background: There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal antibody, selectively targets and...

PERSPECTIVE: The B Cell â Old Player, New Position on the Team

Thu, 14Â FebÂ 2008 00:00:00 -05:00

A phase 2 clinical trial of rituximab in the treatment of multiple sclerosis reported by Hauser et al. in this issue of the Journal (pages 676â688) provides important insights into...

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: Case 36-2007 â A 31-Year-Old Woman with Rash, Fever, and Hypotension

Thu, 22Â NovÂ 2007 00:00:00 -05:00

Dr. Jeffrey O. Greenberg (Medicine): A 31-year-old woman was admitted to this hospital because of facial swelling, fever, and hypotension.

The patient had relapsing and remitting multiple sclerosis, associated with severe...

EDITORIAL: Old Suspects Found Guilty â The First Genome Profile of Multiple Sclerosis

Leena Peltonen, M.D., Ph.D. — Thu, 30Â AugÂ 2007 00:00:00 -05:00

High-resolution genomewide association studies using panels of 300,000 to 1 million single-nucleotide polymorphisms (SNPs) aim to define genetic risk profiles of common diseases. These studies herald a fundamentally new opportunity...

ORIGINAL ARTICLE: Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study

The International Multiple Sclerosis Genetics Consortium — Thu, 30Â AugÂ 2007 00:00:00 -05:00

Background: Multiple sclerosis has a clinically significant heritable component. We conducted a genomewide association study to identify alleles associated with the risk of multiple sclerosis.

Methods: We used DNA microarray technology...

CLINICAL THERAPEUTICS: Natalizumab for Multiple Sclerosis

Richard M. Ransohoff, M.D. — Thu, 21Â JunÂ 2007 00:00:00 -05:00

A 30-year-old woman was evaluated for consideration of treatment options for multiple sclerosis. Two years earlier she had reported having vertigo. The diagnosis of multiple sclerosis was confirmed by clinical...

ORIGINAL ARTICLE: Natural History of Multiple Sclerosis with Childhood Onset

Thu, 21Â JunÂ 2007 00:00:00 -05:00

Background: The course and prognosis of childhood-onset multiple sclerosis have not been well described.

Methods: We used data from 13 adult neurology departments affiliated with the European Database for Multiple Sclerosis...

ORIGINAL ARTICLE: Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis

Thu, 25Â JanÂ 2007 00:00:00 -05:00

Background: Patients with a single episode of neurologic dysfunction and brain magnetic resonance imaging (MRI) scans suggestive of multiple sclerosis are at high risk for clinically definite multiple sclerosis, but...

ORIGINAL ARTICLE: Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis

Thu, 14Â SepÂ 2006 00:00:00 -05:00

Background: Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation for the treatment of relapsing multiple sclerosis.

Methods: We randomly assigned 281 patients to receive oral fingolimod, at a dose...

PERSPECTIVE: Fingolimod and Sphingosine-1-Phosphate â Modifiers of Lymphocyte Migration

Thu, 14Â SepÂ 2006 00:00:00 -05:00

Multiple sclerosis is considered an autoimmune disease in which CD4+ T cells and macrophages destroy oligodendrocytes, which synthesize and maintain axonal myelin sheaths in the central nervous system (CNS). This...

EDITORIAL: Selective Treatment of Multiple Sclerosis

Allan H. Ropper, M.D. — Thu, 02Â MarÂ 2006 00:00:00 -05:00

Natalizumab, a recombinant monoclonal antibody against Î±4 integrins, is the first selective immunomodulating drug for the treatment of multiple sclerosis and, by several criteria, is an advance over current therapies....

REVIEW ARTICLE: Multiple Sclerosis â The Plaque and Its Pathogenesis

Thu, 02Â MarÂ 2006 00:00:00 -05:00

Substantial advances have occurred in the understanding of some of the central mechanisms underlying the inflammation, demyelination, and neurodegeneration that occur in multiple sclerosis since the topic was last reviewed...

ORIGINAL ARTICLE: Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy

Thu, 02Â MarÂ 2006 00:00:00 -05:00

Background: Progressive multifocal leukoencephalopathy (PML) was reported to have developed in three patients treated with natalizumab. We conducted an evaluation to determine whether PML had developed in any other treated...

ORIGINAL ARTICLE: Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

Thu, 02Â MarÂ 2006 00:00:00 -05:00

Background: Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an Î±4 integrin antagonist, appeared to be safe...

ORIGINAL ARTICLE: A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

Thu, 02Â MarÂ 2006 00:00:00 -05:00

Background: Natalizumab is the first Î±4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients...

EDITORIAL: Patients at Risk

Jeffrey M. Drazen, M.D. — Thu, 28Â JulÂ 2005 00:00:00 -05:00

In clinical trials, the term âpatients at riskâ refers to the altruistic people who volunteer to participate in studies of novel treatments. In this issue of the Journal, three reports123...

EDITORIAL: Progressive Multifocal Leukoencephalopathy and Natalizumab â Unforeseen Consequences

Joseph R. Berger, M.D., and Igor J. Koralnik, M.D. — Thu, 28Â JulÂ 2005 00:00:00 -05:00

In this issue of the Journal, there are reports describing in detail three patients in whom progressive multifocal leukoencephalopathy (PML) developed during treatment with natalizumab, a humanized monoclonal antibody against...

ORIGINAL ARTICLE: Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab

Thu, 28Â JulÂ 2005 00:00:00 -05:00

We describe the clinical course of a patient with multiple sclerosis in whom progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the central nervous system, developed during treatment with...

ORIGINAL ARTICLE: Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis

B.K. Kleinschmidt-DeMasters, M.D., and Kenneth L. Tyler, M.D. — Thu, 28Â JulÂ 2005 00:00:00 -05:00

A 46-year-old woman with relapsingâremitting multiple sclerosis died from progressive multifocal leukoencephalopathy (PML) after having received 37 doses of natalizumab (300 mg every four weeks) as part of a clinical...

CLINICAL IMPLICATIONS OF BASIC RESEARCH: Molecular Mimicry in Multiple Sclerosis

Hartmut Wekerle, M.D., and Reinhard Hohlfeld, M.D. — Thu, 10Â JulÂ 2003 00:00:00 -05:00

Most experts believe that multiple sclerosis is an autoimmune disease in which T cells recognize and attack components of the axonal myelin sheath and other features of the central nervous...

ORIGINAL ARTICLE: Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating Event

Thu, 10Â JulÂ 2003 00:00:00 -05:00

Background: Most patients with multiple sclerosis initially present with a clinically isolated syndrome. Despite the fact that clinically definite multiple sclerosis will develop in up to 80 percent of these...

PERSPECTIVE: Do Myelin-Directed Antibodies Predict Multiple Sclerosis?

Jack P. Antel, M.D., and Amit Bar-Or, M.D. — Thu, 10Â JulÂ 2003 00:00:00 -05:00

Multiple sclerosis is characterized by recurrent neurologic events (clinical relapses) that are attributable to multifocal lesions within the central nervous system. Lesions referred to as âactive plaquesâ are characterized by...

EDITORIAL: Î± Integrins as Therapeutic Targets in Autoimmune Disease

Ulrich H. von Andrian, M.D., Ph.D., and Britta Engelhardt, Ph.D. — Thu, 02Â JanÂ 2003 00:00:00 -05:00

In this issue of the Journal, two groups of investigators report on clinical trials of natalizumab, a recombinant monoclonal antibody against Î±4 integrins, for the treatment of multiple sclerosis1 and...

ORIGINAL ARTICLE: A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

Thu, 02Â JanÂ 2003 00:00:00 -05:00

Background: In patients with multiple sclerosis, inflammatory brain lesions appear to arise from autoimmune responses involving activated lymphocytes and monocytes. The glycoprotein Î±4 integrin is expressed on the surface of...

CLINICAL IMPLICATIONS OF BASIC RESEARCH: An Array of Sunshine in Multiple Sclerosis

Thu, 31Â OctÂ 2002 00:00:00 -05:00

Multiple sclerosis is the most common nontraumatic disorder of the central nervous system in young adults. Twenty years after the onset of disease, 90 percent of cases will have entered...

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: Case 34-2002 â A 55-Year-Old Man with Cognitive and Sensorimotor Findings and Intracranial Lesions

Paula Ravin and E. Tessa Hedley-Whyte — Thu, 31Â OctÂ 2002 00:00:00 -05:00

A 55-year-old right-handed man was admitted to the hospital because of difficulty with his handwriting and motor problems in his right leg.

The patient, who was a teacher, had been well...

EDITORIAL: The Lesions of Multiple Sclerosis

Thu, 17Â JanÂ 2002 00:00:00 -05:00

The complex pathogenesis of multiple sclerosis includes inflammation and potentially disabling focal lesions that are associated with heterogeneous, often destructive pathologic changes disseminated throughout the white matter of the central...

ORIGINAL ARTICLE: A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

Thu, 17Â JanÂ 2002 00:00:00 -05:00

Background: In patients with isolated syndromes that are clinically suggestive of multiple sclerosis, such as optic neuritis or brain-stem or spinal cord syndromes, the presence of lesions as determined by...

ORIGINAL ARTICLE: Hepatitis B Vaccination and the Risk of Multiple Sclerosis

Thu, 01Â FebÂ 2001 00:00:00 -05:00

Background: Reports of multiple sclerosis developing after hepatitis B vaccination have led to the concern that this vaccine might be a cause of multiple sclerosis in previously healthy subjects.

Methods: We...

ORIGINAL ARTICLE: Vaccinations and the Risk of Relapse in Multiple Sclerosis

Thu, 01Â FebÂ 2001 00:00:00 -05:00

Background: There has been some concern that vaccination may precipitate the onset of multiple sclerosis or lead to relapses. Since the recent hepatitis B vaccination program in France, there have...

EDITORIAL: Relapse, Remission, and Progression in Multiple Sclerosis

Thu, 16Â NovÂ 2000 00:00:00 -05:00

Multiple sclerosis is the most common cause of severe neurologic disability in adults of northern European origin. At postmortem examination, the cardinal pathological features are multiple areas of focal loss...

ORIGINAL ARTICLE: Relapses and Progression of Disability in Multiple Sclerosis

Thu, 16Â NovÂ 2000 00:00:00 -05:00

Background: The influence of the patterns of onset of multiple sclerosis and relapses of the disease on the time course of irreversible disability is controversial.

Methods: In 1844 patients who had...

REVIEW ARTICLE: Multiple Sclerosis

Thu, 28Â SepÂ 2000 00:00:00 -05:00

More than 100 years has passed since Charcot, Carswell, Cruveilhier, and others described the clinical and pathological characteristics of multiple sclerosis.1 This enigmatic, relapsing, and often eventually progressive disorder of...

ORIGINAL ARTICLE: Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis

Thu, 28Â SepÂ 2000 00:00:00 -05:00

Background: Treatment with interferon beta has been shown to help patients with established multiple sclerosis, but it is not known whether initiating treatment at the time of a first clinical...

EDITORIAL: New Treatment Options for Tremors

Thu, 17Â FebÂ 2000 00:00:00 -05:00

The revival and refinement of stereotactic neurosurgery represent the most important therapeutic advance in the treatment of movement disorders in the past 30 years. The majority of patients who undergo...

ORIGINAL ARTICLE: A Comparison of Continuous Thalamic Stimulation and Thalamotomy for Suppression of Severe Tremor

Thu, 17Â FebÂ 2000 00:00:00 -05:00

Background: Deep-brain stimulation through an electrode implanted in the thalamus was developed as an alternative to thalamotomy for the treatment of drug-resistant tremor. Stimulation is thought to be as effective...

EDITORIAL: Effects of Pregnancy and Delivery on Disease Activity in Multiple Sclerosis

Thu, 30Â JulÂ 1998 00:00:00 -05:00

Multiple sclerosis, an organ-specific autoimmune disease of the central nervous system, affects 250,000 to 350,000 persons in the United States. It is at least twice as common among women as...

ORIGINAL ARTICLE: Rate of Pregnancy-Related Relapse in Multiple Sclerosis

Thu, 30Â JulÂ 1998 00:00:00 -05:00

Background: and Methods: Multiple sclerosis often occurs in young women, and the effect of pregnancy on the disease is poorly understood. We studied 254 women with multiple sclerosis during 269...

ORIGINAL ARTICLE: Axonal Transection in the Lesions of Multiple Sclerosis

Thu, 29Â JanÂ 1998 00:00:00 -05:00

Background: Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system and is the most common cause of neurologic disability in young adults. Despite antiinflammatory or immunosuppressive therapy,...

REVIEW ARTICLE: Management of Multiple Sclerosis

Thu, 27Â NovÂ 1997 00:00:00 -05:00

Multiple sclerosis is a common disease of the central nervous system affecting approximately 1 million young adults, mostly women, worldwide.1 It is characterized by episodic neurologic symptoms that are often...

NEJM â Collection Updates for Multiple Sclerosis

EDITORIAL: Oral Therapy for Multiple Sclerosis â Sea Change or Incremental Step?

ORIGINAL ARTICLE: A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

ORIGINAL ARTICLE: Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

ORIGINAL ARTICLE: A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

CLINICAL IMPLICATIONS OF BASIC RESEARCH: Gray-Matter Injury in Multiple Sclerosis

ORIGINAL ARTICLE: Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy

ORIGINAL ARTICLE: Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab

ORIGINAL ARTICLE: Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab

PERSPECTIVE: Reemergence of PML in Natalizumab-Treated Patients â New Cases, Same Concerns

BOOK REVIEW:

EDITORIAL: Multiple Lessons for Multiple Sclerosis

ORIGINAL ARTICLE: Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

ORIGINAL ARTICLE: B-Cell Depletion with Rituximab in RelapsingâRemitting Multiple Sclerosis

PERSPECTIVE: The B Cell â Old Player, New Position on the Team

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: Case 36-2007 â A 31-Year-Old Woman with Rash, Fever, and Hypotension

EDITORIAL: Old Suspects Found Guilty â The First Genome Profile of Multiple Sclerosis

ORIGINAL ARTICLE: Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study

CLINICAL THERAPEUTICS: Natalizumab for Multiple Sclerosis

ORIGINAL ARTICLE: Natural History of Multiple Sclerosis with Childhood Onset

ORIGINAL ARTICLE: Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis

ORIGINAL ARTICLE: Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis

PERSPECTIVE: Fingolimod and Sphingosine-1-Phosphate â Modifiers of Lymphocyte Migration

EDITORIAL: Selective Treatment of Multiple Sclerosis

REVIEW ARTICLE: Multiple Sclerosis â The Plaque and Its Pathogenesis

ORIGINAL ARTICLE: Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy

ORIGINAL ARTICLE: Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

ORIGINAL ARTICLE: A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

EDITORIAL: Patients at Risk

EDITORIAL: Progressive Multifocal Leukoencephalopathy and Natalizumab â Unforeseen Consequences

ORIGINAL ARTICLE: Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab

ORIGINAL ARTICLE: Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis

CLINICAL IMPLICATIONS OF BASIC RESEARCH: Molecular Mimicry in Multiple Sclerosis

ORIGINAL ARTICLE: Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating Event

PERSPECTIVE: Do Myelin-Directed Antibodies Predict Multiple Sclerosis?

EDITORIAL: Î± Integrins as Therapeutic Targets in Autoimmune Disease

ORIGINAL ARTICLE: A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

CLINICAL IMPLICATIONS OF BASIC RESEARCH: An Array of Sunshine in Multiple Sclerosis

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: Case 34-2002 â A 55-Year-Old Man with Cognitive and Sensorimotor Findings and Intracranial Lesions

EDITORIAL: The Lesions of Multiple Sclerosis

ORIGINAL ARTICLE: A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

ORIGINAL ARTICLE: Hepatitis B Vaccination and the Risk of Multiple Sclerosis

ORIGINAL ARTICLE: Vaccinations and the Risk of Relapse in Multiple Sclerosis

EDITORIAL: Relapse, Remission, and Progression in Multiple Sclerosis

ORIGINAL ARTICLE: Relapses and Progression of Disability in Multiple Sclerosis

REVIEW ARTICLE: Multiple Sclerosis

ORIGINAL ARTICLE: Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis

EDITORIAL: New Treatment Options for Tremors

ORIGINAL ARTICLE: A Comparison of Continuous Thalamic Stimulation and Thalamotomy for Suppression of Severe Tremor

EDITORIAL: Effects of Pregnancy and Delivery on Disease Activity in Multiple Sclerosis

ORIGINAL ARTICLE: Rate of Pregnancy-Related Relapse in Multiple Sclerosis

ORIGINAL ARTICLE: Axonal Transection in the Lesions of Multiple Sclerosis

REVIEW ARTICLE: Management of Multiple Sclerosis

NEJM â Collection Updates for Multiple Sclerosis

EDITORIAL: Oral Therapy for Multiple Sclerosis â Sea Change or Incremental Step?

PERSPECTIVE: Reemergence of PML in Natalizumab-Treated Patients â New Cases, Same Concerns

ORIGINAL ARTICLE: B-Cell Depletion with Rituximab in RelapsingâRemitting Multiple Sclerosis

PERSPECTIVE: The B Cell â Old Player, New Position on the Team

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: Case 36-2007 â A 31-Year-Old Woman with Rash, Fever, and Hypotension

EDITORIAL: Old Suspects Found Guilty â The First Genome Profile of Multiple Sclerosis

PERSPECTIVE: Fingolimod and Sphingosine-1-Phosphate â Modifiers of Lymphocyte Migration

REVIEW ARTICLE: Multiple Sclerosis â The Plaque and Its Pathogenesis

EDITORIAL: Progressive Multifocal Leukoencephalopathy and Natalizumab â Unforeseen Consequences

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: Case 34-2002 â A 55-Year-Old Man with Cognitive and Sensorimotor Findings and Intracranial Lesions